Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist

A case report

Aiko Terakawa, MD, Daisuke Chujo, MD, PhD, Kazuki Yasuda, MD, PhD, Keisuke Ueno, MD, Tomoka Nakamura, MD, Shoko Hamano, MD, Mitsuru Ohsugi, MD, Akiyo Tanabe, MD, PhD, Kohjiro Ueki, MD, PhD, Hiroshi Kajio, MD, PhD

Abstract

Rationale: Maturity-onset diabetes of the young type 5 (MODY 5) is a form of monogenic diabetes that is often accompanied by pancreatic dysfunction. To date, no cases of MODY 5 treated with glucagon-like peptide-1 receptor agonist (GLP-1RA) have been reported. We present the first case of MODY 5 treated with GLP-1RA.

Patient concerns: A 17-year-old woman, with a history of being operated for congenital ileal atresia at birth, was admitted to our hospital due to hyperglycemia. She had been clinically diagnosed with type 1 diabetes 1 month prior, and administered 14 units of insulin glargine 300 U/mL per day.

Diagnosis: She had hypopotassemia, hypomagnesaemia, pancreatic body, and tail defects, multiple renal cysts, and a family history of diabetes, and urogenital anomaly. Genetic testing revealed heterozygous deletion of hepatocyte nuclear transcription factor-1 beta, leading to the diagnosis of MODY 5.

Interventions: The patient was treated with multiple daily insulin injections for 9 days (22 units/d) before administration of GLP-1RA, and then liraglutide was initiated.

Outcomes: Liraglutide treatment (0.6 mg/d) alone maintained the patient’s glycated hemoglobin level below 7.0% for at least 12 months after discharge. A higher dose, 0.9 mg/d, of liraglutide was not tolerated by the patient due to nausea. Serum levels of C-peptide immunoreactivity were 1.15 ng/mL and 1.91 ng/mL, respectively, after 6 and 12 months of liraglutide therapy.

Lessons: GLP-1RA might be effective at regulating glucose metabolism by utilizing residual pancreatic endocrine function in patients with MODY 5. Imaging and genetic screening were helpful in the diagnosis of MODY 5.

Abbreviations: CPR = C-peptide immunoreactivity, FPG = fasting plasma glucose, Gla-U300 = insulin glargine 300 U/mL, GLP-1RA = glucagon-like peptide-1 receptor agonist, HbA1c = glycated hemoglobin, HNF = hepatocyte nuclear transcription factor, MODY = maturity-onset diabetes of the young, PAX6 = paired box 6.

Keywords: diabetes, glucagon-like peptide-1 receptor agonist, liraglutide, maturity-onset diabetes of the young type 5

Editor: Maya Saranathan.

Written informed consent was obtained from the patient for genetic analyses and inclusion of her clinical and imaging details in the manuscript for the purpose of publication.

The authors have no funding and conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

* Correspondence: Daisuke Chujo, Center for Clinical Research, Toyama University Hospital, 2630 Sugitani, Toyama 930-0194, Japan (e-mail: dchujo@med.u-toyama.ac.jp).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

How to cite this article: Terakawa A, Chujo D, Yasuda K, Ueno K, Nakamura T, Hamano S, Ohsugi M, Tanabe A, Ueki K, Kajio H. Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report. Medicine 2020;99:35(e21939).

Received: 18 December 2019 / Received in final form: 17 June 2020 / Accepted: 28 July 2020.

http://dx.doi.org/10.1097/MD.00000000000021939
1. Introduction

Maturity-onset diabetes of the young (MODY), a form of autosomal dominant monogenic diabetes, is characterized by early onset, typically before the age of 25, and progressive dysfunction of pancreatic beta cells. Previous reports have indicated that MODY is caused by pathogenic mutations in at least 14 different genes.[1] Since it is often difficult to distinguish MODY from other types of diabetes, such as type 1 diabetes, without conducting a proper genetic analysis, some MODY cases may be misdiagnosed. MODY type 5 (MODY 5), which is caused by a mutation of the gene encoding hepatocyte nuclear transcription factor-1 beta (HNF1B), displays variable phenotype, including young-onset diabetes,[2] malformation of the pancreas,[3,4] exocrine pancreatic dysfunction,[3] urogenital abnormalities,[5] impaired renal function,[6] renal cysts,[6,7] hypomagnesemia,[8] elevated liver enzymes,[9] and neurocognitive defects.[10] Therefore, diagnostic imaging may be helpful in diagnosing MODY 5.

To date, no cases of MODY 5 treated with glucagon-like peptide-1 receptor agonist (GLP-1RA) have been reported. The current study describes the first case of MODY 5 treated with the GLP-1RA, liraglutide, which exerted protective effects against pancreatic beta cell dysfunction.[11,12]

2. Case report

A 17-year-old woman with a 3-month history of thirst, polydipsia, and polyuria underwent urine glucose screening at school where glucosuria was detected for the first time. The patient underwent surgery at birth to correct congenital ileal atresia, but had no history of hearing loss. She underwent examination at a clinic where her fasting plasma glucose (FPG) level and glycated hemoglobin (HbA1c) value were found to be 276mg/dL and 9.7%, respectively. Based on her young age and absence of obesity, the patient was diagnosed with type 1 diabetes and insulin glargine 300U/mL (Gla-U300) was started at 14 units/d. The treatment failed to sufficiently control the blood glucose level and the patient was admitted to our hospital for diabetes treatment as well as for education. Her family history is shown in Figure 1. Her mother and maternal grandmother developed diabetes at the age of 32 and 50, respectively, and were treated with oral medication. Her mother and maternal aunt had bicornuate uterus, and the latter also had unilateral aplasia of the kidneys. There was no family history of hearing loss. The patient’s height was 154cm and her weight was 41.4kg (body mass index of 17.3kg/m²). Physical examination revealed no abnormalities. Laboratory investigations revealed an FPG level of 80mg/dL and HbA1c value of 9.5% (Table 1). Glucagon stimulation test under a stable blood glucose level revealed that serum C-peptide immunoreactivity (CPR) was 1.01ng/mL (PG 92mg/dL) and 2.53ng/mL (PG 117mg/dL), before and 6 minutes after glucagon stimulation, respectively (ΔCPR of 1.52ng/mL). According to these data, her endogenous insulin secretion remained in addition, she displayed low levels of serum potassium (3.0 mEq/L) and serum magnesium (1.0mg/dL). No islet-related autoantibodies, including insulin autoantibodies, anti-glutamic acid decarboxylase antibodies, anti-insulinoma-associated protein-2 antibodies, or anti-zinc transporter-8 antibodies, were detected in her blood, suggesting the absence of autoimmune diabetes. As serum lactate and pyruvate were within normal limits, and mitochondrial DNA point mutations, including A3242G, were not detected in genetic screening tests targeting 10 point mutations, mitochondrial diabetes was excluded.

Contrast-enhanced computed tomography was performed to assess the morphology of the pancreas. The images showed defects in the pancreatic body and tail, as well as the presence of multiple renal cysts (Fig. 2). Contrast-enhanced magnetic

Figure 1. The patient’s family history. The numbers in circles and squares indicate the age of female and male family members, respectively. The pink-filled circles denote diabetic family members.
resonance imaging revealed that the partial pancreatic defects were due to agenesis of the dorsal pancreas, rather than fat displacement. The p-aminobenzoic acid excretion index was 35.4%, indicating insufficiency of exocrine pancreatic function. Based on these findings, and the patient’s hypopotassemia, hypomagnesaemia, agenesis of dorsal pancreas, multiple renal cysts, and family history of diabetes, and renal and urogenital abnormalities, MODY 5 was suspected. Screening of MODY-related genes using multiple ligation-dependent probe amplification detected a heterozygous deletion of HNF1B (Fig. 3), leading to a definitive diagnosis of MODY 5.

Immediately following admission to our hospital, multiple-dose injection therapy with insulin lispro (maximum requirement was 9 units/d) and Gla-U300 (maximum requirement was 13 units/d) was commenced. After 9 days of insulin therapy, the patient was started on liraglutide to prevent dysfunction of the remaining pancreatic beta cells. According to flash glucose monitoring (FreeStyle Libre, Abbott Japan, Japan) data, before liraglutide was administered, the patient’s blood glucose was within the target range (80–140 mg/dL) 39% of the time under the treatment with 9 units/d of insulin lispro and 13 units of Gla-U300 (Fig. 4A). After 6 days of liraglutide treatment, this value improved to 65% (Fig. 4B), under the treatment with just 7 units/d of Gla-U300, indicating a reduction of 15 units in the total daily insulin dosage, and 0.9 mg/d of liraglutide. Notably, HbA1c was maintained below 7% for at least for 12 months after the patient was discharged with 0.6 mg of liraglutide a day (a higher dose was not tolerated by the patient due to nausea), without any insulin injections. Serum CPR level was 1.15 ng/mL (FPG 135 mg/dL) and 1.91 ng/mL (FPG 115 mg/dL) after 6 and 12 months of liraglutide therapy, respectively, indicating that endogenous insulin secretion was maintained during the treatment period.

3. Discussion

Approximately 1% to 2% of all diabetes cases are diagnosed as MODY.[13] In the pediatric diabetes population, the prevalence of the 13 MODY variants is 2.1%. Genetic variants related to MODY are found in 5.1% of patients who were pre-diagnosed

---

### Table 1

| Blood test       | Value   | U-PABA elimination rate |
|------------------|---------|-------------------------|
| WBC /μL          | 8580    |                         |
| Hb g/dL          | 13.8    |                         |
| Plt /μL          | 27.6 × 10^9 |                         |
| Alb U/L          | 6.9     |                         |
| AST U/L          | 15      |                         |
| ALT U/L          | 7       |                         |
| γ-GTP U/L        | 8       |                         |
| BUN mg/dL        | 14.6    |                         |
| Cr mg/dL         | 0.52    |                         |
| Na mg/dL         | 145     |                         |
| Cl mg/dL         | 3.4     |                         |
| Ca mg/dL         | 102     |                         |
| P mg/dL          | 9.9     |                         |
| Mg mg/dL         | 1.0     |                         |
| FPG mg/dL        | 80      |                         |
| GA %             | 25.5    |                         |
| HbA1c mg/gCre    | 9.4     |                         |
| Glucagon stimulation test | 0 min | 6 min |
| PG mg/dL         | 92      | 117                      |
| CPR mg/dL        | 1.02    | 2.03                     |

**Laboratory data on admission.**

- **Alb =** albumin, **AST =** aspartate transaminase, **ALT =** alanine transaminase, **BUN =** blood nitrogen nitrate, **Ca =** calcium, **Cl =** chloride, **CPR =** C-peptide immunoreactivity, **Cre =** creatinine, **FPG =** fasting plasma glucose, **GAD-Ab =** glutamic acid decarboxylase antibody, **IA-2-Ab =** insulinoma associated antigen-2 antibody, **Insulin-Ab =** insulin antibody, **K =** potassium, **Mg =** magnesium, **Na =** sodium, **P =** phosphorus, **PCO2 =** partial pressure of carbon dioxide, **PG =** plasma glucose, **pH =** potential hydrogen, **Plt =** platelet, **U-BUN =** urinary blood nitrogen nitrate, **U-CPR =** urinary C-peptide immunoreactivity, **U-K =** urinary potassium, **U-PABA =** urinary p-aminobenzoic acid, **WBC =** white blood cell, **ZnT8-Ab =** zinc transporter-8 antibody.
Figure 3. Analysis of maturity-onset diabetes of the young-related genes by multiple ligation-dependent probe amplification. The blue dash-line oval indicates heterozygous deletion of the entire glycated hemoglobin gene, as shown by the defect in a copy of the gene. GCK = glucokinase, HNF = hepatocyte nuclear factor.

Figure 4. (A) Flash glucose monitoring results on day 8 in the hospital. The patient received 9 units of insulin lispro and 13 units of insulin glargine 300 U/mL per day since admission. (B) Flash glucose monitoring results on day 15 in the hospital. The patient received 7 units/d of insulin glargine 300 U/mL and 0.9 mg/d of liraglutide. The gray band indicates the target range for blood glucose concentration.
with type 2 diabetes. 0.45% of patients pre-diagnosed with antibody-positive type 1 diabetes, and 4.4% of patients pre-diagnosed with antibody-negative type 1 diabetes. 

Fourteen different genetic mutations related to MODY have been identified, including mutations in genes encoding hepatocyte nuclear factor-4 alfa (HNF-4; MODY 1), glucokinase (GCK; MODY 2), HNF-1a (MODY 3), and HNF-1B (MODY 5). In Japan, the prevalence of MODY 1, MODY 2, MODY 3, and MODY 5 among all MODY cases is 7.6%, 36.3%, 39.4%, and 13.6%, respectively.

HNF-1B, which belongs to the homeodomain-containing family of transcription factors, is expressed in tissues such as the liver, pancreas, kidney, urogenital tract, and intestine. MODY 5 manifests in various forms in the HNF-1B-expressing organs. In the current case, defects of the pancreatic body and tail, multiple renal cysts, hypopotassemia, and hypomagnesaemia were identified. In approximately 50% of MODY 5 patients, the disease is caused by whole HNF1B deletions, where 50% of the deletions are de novo. 

Compared to patients with HNF1B intragenic mutations, those with HNF1B deletions have better renal prognoses, but are more likely to exhibit neuro-developmental disorders. HNF1B is located on chromosome 17q12, which also contains 14 other genes. HNF1B deletion may be accompanied by deletions of neighboring genes, resulting in variable phenotypes in patients. Interestingly, Japanese monozygotic twins with MODY 5, both of whom displayed a microdeletion of 17q12 including HNF1B, exhibited malformation of the pancreas and kidneys, hypomagnesaemia, and hyperuricemia. However, they displayed different renal and pancreatic manifestations; one had severely impaired endogenous insulin secretion and mild renal dysfunction, while the other had severe renal dysfunction and relatively preserved endogenous insulin secretion.

Thus, slight differences in genetic information observed in monozygotic twins, such as those in mitochondrial DNA and DNA methylation, may affect the phenotypic manifestation of MODY 5.

In most MODY 5 patients, endogenous insulin secretion progressively declines from an early stage. One reason for such a decline is low pancreatic beta cell mass due to pancreatic malformation, which is seen in 50% to 60% of MODY5 cases. Since MODY 5 patients usually show absolute insulin deficiency at diagnosis, many require permanent insulin therapy. In addition, beta cell-selective HNF1B deletion impairs insulin secretion in mice. MODY 5 patients also show reduced insulin sensitivity of endogenous glucose production; whereas insulin-induced peripheral glucose uptake is normal.

In this case, the patient was able to maintain appropriate blood glucose levels with liraglutide alone for a year. Liraglutide upregulates paired box 6 (PAX6) expression. PAX6, which is downregulated in pancreatic progenitor cells from MODY5 patients (HNF1B-/-)-human-induced pluripotent stem cells, plays an important role in the differentiation of islet cells. We speculated that liraglutide might be effective in reversing abnormalities of glucose metabolism due to HNF1B mutation via its stimulation of PAX6 expression.

Liraglutide protects against beta cell apoptosis, suggesting its suitability for treating MODY 5 patients who show partial defects in pancreatic beta cells. Additionally, reduced HNF1B expression in the liver causes insulin resistance via impaired insulin signaling, accelerates gluconeogenesis, and increases dipeptidyl peptidase-4 level. The above findings indicate that liraglutide, which improves hepatic insulin resistance, shows potential as a treatment option for MODY 5.

There are certain limitations to this study. First, the recovery from glucotoxicity and the improvement of eating habits during hospitalization might affect the patient’s glycemic control. Second, due to time constraints, the long-term protective effects of GLP-1RA on beta cells were not assessed.

4. Conclusions

We have presented a case of a MODY 5 patient who achieved appropriate glycemic control with a GLP-1R, liraglutide. Imaging and genetic screening were helpful in the differential diagnosis between type 1 diabetes and MODY 5. An early and exact diagnosis via genetic testing is important for selecting appropriate hypoglycemic agents and predicting the patient’s prognosis.

More cases of MODY 5 need to be investigated to confirm the efficacy of GLP-1RA for treating this disease.

Acknowledgments

We would like to thank Editage (Tokyo, Japan; www.editage.jp) for English language editing.

Author contributions

Supervision: Daisuke Chuo.

Writing – original draft: Aiko Terakawa.

Writing – review & editing: Daisuke Chuo, Kazuki Yasuda, Keisuke Ueno, Tomoka Nakamura, Shoko Hamano, Mitsuru Ohsugi, Akiyo Tanabe, Kohjiro Ueki, Hiroshi Kajio.

References

[1] Prudente S, Jungtrakoon P, Marucci A, et al. Loss-of-function mutations in APLP1 in familial diabetes mellitus. Am J Hum Genet 2015;97:177–85.
[2] Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor 1beta gene (TCF2) associated with MODY. Nat Genet 1997; 17:384–5.
[3] Bellané-Chantelot C, Chauveau D, Gautier JF, et al. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med 2004;140:510–7.
[4] Haldorsen IS, Vesterhus M, Raeder H, et al. Lack of pancreatic body and tail in HNF1B mutation carriers. Diabetes Med 2008;25:782–7.
[5] Bingham C, Ellard S, Cole TR, et al. Solitary functioning kidney and diverse genital tract malformations associated with hepatocyte nuclear factor-1beta mutations. Kidney Int 2002;61:1243–51.
[6] Paguer S, Decramer S, Chassaing N, et al. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood. Kidney Int 2011;80:768–76.
[7] Edghill EL, Bingham C, Ellard S, et al. Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J Med Genet 2006;43:84–90.
[8] Adalat S, Woolf AS, Johnstone KA, et al. HNF1B mutations associated with hypomagnesaemia and renal magnesium wasting. J Am Soc Nephrol 2009;20:1123–31.
[9] Iwasaki N, Ogata M, Tomonaga O, et al. Liver and kidney function in Japanese patients with maturity-onset diabetes of the young. Diabetes Care 1998;21:2144–8.
[10] Dubois-Laforgue D, Bellané-Chantelot C, Charles P, et al. Intellectual disability in patients with MODY due to hepatocyte nuclear factor 1B (HNF1B) molecular defects. Diabetes Metab 2017;43:89–92.
[11] Ding M, Fang QH, Cui YT, et al. Liraglutide prevents 8-cell apoptosis via inactivation of NOX2 and its related signalling pathway. J Diabetes Complications 2019;33:267–77.
[12] Kapodistria K, Tsihlaris EP, Kotsoopoulos E, et al. Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic 8-cell apoptosis. J Cell Mol Med 2018;22:2970–80.
Fajans SS, Bell GL. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 2011;34:1878–84.

Johnson SR, Ellis JJ, Leo PJ, et al. Comprehensive genetic screening: the prevalence of maturity-onset diabetes of the young gene variants in a population-based childhood diabetes cohort. Pediatr Diabetes 2019;20:57–64.

Horikawa Y. Maturity-onset diabetes of the young as a model for elucidating the multifactorial origin of type 2 diabetes mellitus. J Diabetes Invest 2018;9:704–12.

Decramer S, Parant O, Beaufils S, et al. Anomalies of the TCF2 gene are the main cause of fetal bilateral hyperechogenic kidneys. J Am Soc Nephrol 2007;18:923–33.

Ulimski T, Lescure S, Beaufils S, et al. Renal phenotype related to hepatocyte nuclear factor-1beta (TCF2) mutations in a pediatric cohort. J Am Soc Nephrol 2006;17:497–503.

Dubois-Laforgue D, Cornu E, Saint-Martin C, et al. Diabetes, associated clinical spectrum, long-term prognosis, and genotype/phenotype correlations in 201 adult patients with hepatocyte nuclear factor 1B (HNF1B) molecular defects. Diabetes Care 2017;40:1436–43.

Cissold RL, Shaw-Smith C, Turpenny P, et al. Chromosome 17q12 microdeletions but not intragenic HNF1B mutations link developmental kidney disease and psychiatric disorder. Kidney Int 2016;90:203–11.

Heidet L, Decramer S, Pawtowski A, et al. Spectrum of HNF1B mutations in a large cohort of patients who harbour renal diseases. Clin J Am Soc Nephrol 2010;5:1079–90.

Moreno-De-Luca D, Mulle JG, Kaminsky EB, et al. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am J Hum Genet 2010;87:618–30.

Ohara Y, Okada Y, Yamada T, et al. Phenotypic differences and similarities of monozygotic twins with maturity-onset diabetes of the young type 5. J Diabetes Investig 2019;10:963–71.

Horikawa Y, Enya M, Fushimi N, et al. Screening of diabetes of youth for hepatocyte nuclear factor 1 mutations: clinical phenotype of HNF1ß-related maturity-onset diabetes of the young and HNF1a-related maturity-onset diabetes of the young in Japanese. Diabet Med 2014;31:721–7.

Yorifuji T, Fujimaru R, Hosokawa Y, et al. Comprehensive molecular analysis of Japanese patients with pediatric-onset MODY-type diabetes mellitus. Pediatr Diabetes 2012;13:26–32.

Roehlen N, Hilger H, Stock F, et al. 17q12 deletion syndrome as a rare cause for diabetes mellitus type MODY 5. J Clin Endocrinol Metab 2018;103:3601–10.

Wang L, Coffman C, Thomas MK, et al. Selective deletion of the Hnf1beta (MODY5) gene in beta-cells leads to altered gene expression and defective insulin release. Endocrinology 2004;145:3941–9.

Brackenridge A, Pearson ER, Shojaee-Moradie F, et al. Contrasting insulin sensitivity of endogenous glucose production rate in subjects with hepatocyte nuclear factor-1beta and -alpha mutations diabetes. Diabetes 2006;55:405–11.

Li Y, Zheng J, Shen Y, et al. Comparative Study of liraglutide and insulin glargine on glycemic control and pancreatic β-cell function in db/db mice. Med Sci Monit 2018;24:3293–300.

Teo AK, Lau HH, Valdez IA, et al. Early developmental perturbations in a human stem cell model of MODY5/HNF1B pancreatic hypoplasia. Stem Cell Rep 2016;6:357–67.

Ashery-Padan R, Zhou X, Marquardt T, et al. Conditional inactivation of Pax6 in the pancreas causes early onset of diabetes. Dev Biol 2004;269:479–88.

Swisa A, Avrahami D, Eden N, et al. PAX6 maintains β cell identity by repressing genes of alternative islet cell types. J Clin Invest 2017;127:230–43.

Kornfeld JW, Baizel C, Künzer AC, et al. Obesity-induced over-expression of mR-802 impairs glucose metabolism through silencing of Hnf1b. Nature 2013;494:111–5.

Long Z, Cao M, Su S, et al. Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1-mediated regulation of superoxide. Free Radic Biol Med 2017;113:71–83.

Qin Y, Chen M, Yang Y, et al. Liraglutide improves hepatic insulin resistance via the canonical Wnt signaling pathway. Mol Med Rep 2018;17:7372–80.